The Role of Allogeneic Transplantation in the Treatment of Multiple Myeloma

References

• Corradini, P., Boccadoro, M., Voena, C. and Pileri, A. (1993). Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined Cμ sequence in immunoglobulin (IgG) and (IgA) secreting multiple myelomas. J. Exp. Med., 178, 1091–1096.
   PubMed Web of Science ®Google Scholar
• Corradini, P., Astolfi, M., Cherasco, C. et al. (1997). Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood, 89, 724–731.
   PubMed Web of Science ®Google Scholar
• Caligaris Cappio, F., Cavo, M., De Vincentiis, A. et al. (1996). Peripheral blood stem cell transplantation for the treatment of multiple myeloma: biological and clinical implications. Haematologica, 81, 356–375.
   PubMed Web of Science ®Google Scholar
• Hallek, M., Bergsagel, P. L. and Anderson, K. C. (1998). Multiple myeloma: increasing evidence for a multistep transformation process. Blood, 91, 3–21.
   PubMed Web of Science ®Google Scholar
• Bataille, R. and Harousseau, J. L. (1997). Multiple myeloma. New Eng. J. Med., 336, 1657–1664.
   PubMed Web of Science ®Google Scholar
• Boccadoro, M. and Pileri, A. (1995). Prognostic factors in multiple myeloma. In: Malpas, J. S., Bergsagel, D. E. and Kyle, R. A. (Eds.). Myeloma: biology and management. New York, pp. 251–270.
   Google Scholar
• Boccadoro, M., Marmont, F., Tribalto, M. et al. (1991). Multiple myeloma: alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan and prednisone (MP) even in high-risk patients. J. Clin. Oncol., 9, 444–448.
   PubMed Web of Science ®Google Scholar
• Alexanian, R., Dimopoulos, M. A., Hester, J., Delasalle, K. B. and Champlin, R. (1994). Early myeloablative therapy for multiple myeloma. Blood, 84, 4278–4282.
   PubMed Web of Science ®Google Scholar
• Bensinger, W. I., Rowley, S. D., Demirer, T. et al. (1996). High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. J. Clin Oncol, 14, 1447–1456.
   PubMed Web of Science ®Google Scholar
• Attal, M., Harousseau, J. L., Stoppa, A. M. et al. (1996). A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N. Eng. J. Med., 335, 91–97.
   PubMed Web of Science ®Google Scholar
• Gianni, A. M., Tarella, C., Bregni, M. et al. (1994). High-dose sequential (HDS) chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma. J. Clin. Oncol., 12, 503–509.
   PubMed Web of Science ®Google Scholar
• Harousseau, J. L., Attal, M., Divine, M. et al. (1995). Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French registry on autologous transplantation in multiple myeloma. Blood, 85, 3077–3085.
   PubMed Web of Science ®Google Scholar
• Gahrton, G., Tura, S., Ljungman, P. et al. (1991). Allogeneic bone marrow transplantation in multiple myeloma. N. Eng. J. Med., 325, 1267–1273.
   PubMed Web of Science ®Google Scholar
• Gahrton, G. (1996). Allogeneic bone marrow transplantation in multiple myeloma. Br. J. Haematol., 92, 251–254.
   PubMed Web of Science ®Google Scholar
• Tura, S. and Cavo, M. (1982). Allogeneic bone marrow transplantationin multiple myeloma. Hematol. Oncol Clin North Am., 6, 425–435.
   Google Scholar
• Tura, S., Cavo, M., Rosti, G. et al. (1989). Allogeneic bone marrow transplantation for multiple myeloma. Bone Marrow Transplant, 4, 106–108.
   PubMed Web of Science ®Google Scholar
• Tura, S., Cavo, M., Baccarani, M., Ricci, P. and Gobbi, M. (1986). Bone marrow transplantation in multiple myeloma. Scan J. Haematol., 36, 176–179.
   PubMedGoogle Scholar
• Bensinger, W. I., Buckner, C. D., Anasetti, C. et al. (1996). Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood, 88, 2787–2793.
   PubMed Web of Science ®Google Scholar
• Barlogie, B., Jagannath, S., Vesole, D. and Tricot, G. (1995). Autologous and allogeneic transplants for multiple myeloma. Sem Hematol., 32, 31–34.
   PubMed Web of Science ®Google Scholar
• Cavo, M., Beni, M., Cirio, M. T., Gozzetti, A. and Tura, S. (1995). Allogeneic bone marrow transplantation for the treatment of multiple myeloma. Stem cells, 13(Suppl 2), 126–131.
   PubMed Web of Science ®Google Scholar
• Selby, P. J., McElwain, T. J., Nandi, A. C. et al. (1987). Multiple myeloma treated with high dose intravenous melphalan. Br. J. Haematol., 66, 55–62.
   PubMed Web of Science ®Google Scholar
• McElwain, T. J. and Powles, R. L. (1983). High-dose intravenous melphalan for plasma cell leukemia and myeloma. Lancet, 1, 822–824.
   Google Scholar
• Barlogie, B., Hall, R., Zander, A., Dicke, K. and Alexanian, R. (1986). High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood, 67, 1298–1301.
   PubMed Web of Science ®Google Scholar
• Jagannath, S., Barlogie, B., Dicke, K. et al. (1990). Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors. Blood, 76, 1860–1866.
   PubMed Web of Science ®Google Scholar
• Harousseau, J. L., Milpied, N., La Porte, J. P. et al. (1992). Double-intensive therapy in high-risk multiple myeloma. Blood, 79, 2827–2833.
   PubMed Web of Science ®Google Scholar
• Attal, M., Huguet, F., Schlaifer, D. et al. (1992). Intensive combined therapy for previously untreated aggressive myeloma. Blood, 79, 1130–1136.
   PubMed Web of Science ®Google Scholar
• Cunningham, D., Paz-Arez, L., Milan, S. et al. (1994). High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J. Clin. Oncol., 12, 759–763.
   PubMed Web of Science ®Google Scholar
• Vesole, D. H., Barlogie, B., Jagannath, S. et al. (1994). High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood, 84, 950–956.
   PubMed Web of Science ®Google Scholar
• Fermand, J. P., Chevret, S., Ravaud, P. et al. (1993). High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients. Blood, 82, 2005–2009.
   PubMed Web of Science ®Google Scholar
• Gore, M. E., Selby, P. J., Viner, C. et al. (1989). Intensive treatment of multiple myeloma and criteria for complete remission. Lancet, 2, 879–881.
   PubMed Web of Science ®Google Scholar
• Alegre, A., Lamana, M., Arranz, R. et al. (1995). Busulfan and melphalan as conditioning regimen for autologous peripheral blood stem cell transplantation. Br. J. Haematol., 91, 380–386.
   PubMed Web of Science ®Google Scholar
• Bjorkstrand, B., Goldstone, A. H., Lungman, P. et al. (1994). Prognostic factors in autologous stem cell transplantation for multiple myeloma: an EBMT study. Leuk Lymphoma, 15, 265–272.
   PubMed Web of Science ®Google Scholar
• Barlogie, B., Jagannath, S., Vesole, D. H. et al. (1997). Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood, 89, 789–793.
   PubMed Web of Science ®Google Scholar
• Attal, M., Payen, C., Facom, T. et al. (1998). Single versus double transplant in myeloma: a randomized trial of the “Inter Groupe Français du Myelome”. Bone Marrow Transplant, 21(Suppl. 1), S206.
   Google Scholar
• Gribben, J. G., Freedman, A. S., Neuberg, D. et al. (1991). Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N. Engl. J. Med., 325, 1525–1533.
   PubMed Web of Science ®Google Scholar
• Brenner, M. K., Rill, D. R., Moen, R. C. et al. (1993). Genemarking to trace origin of relapse after autologous bone marrow transplantation. Lancet, 341, 85–86.
   PubMed Web of Science ®Google Scholar
• Tricot, G., Gazitt, Y., Leemhuis, T. et al. (1998). Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma. Blood, 91, 4489–4495.
   PubMed Web of Science ®Google Scholar
• Gahrton, G., Ringdén, O., Lonnqvist, B., Lindqvist, R. and Ljungman, P. (1982). Bone marrow transplantation in three patients with multiple myeloma. Acta. Med. Scand, 219, 523–527.
   Google Scholar
• Buckner, C. D., Fefer, A., Bensigner, W. I. et al. (1989). Marrow transplantation for malignant plasma cell disorders: summary of the Seattle experience. Eur. J. Haematol., 43, 186–190.
   PubMed Web of Science ®Google Scholar
• Gahrton, G., Tura, S., Ljungman, P. et al. (1995). Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J. Clin. Oncol., 13, 1312–1322.
   PubMed Web of Science ®Google Scholar
• Bensinger, W. I., Buckner, C. D., Clift, R. A. et al. (1992). A phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma. J. Clin. Oncol., 10, 1492–1497.
   PubMed Web of Science ®Google Scholar
• Bjorkstrand, B., Ljungman, P., Svensson, H. et al. (1996). Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood, 88, 4711–4718.
   PubMed Web of Science ®Google Scholar
• Mehta, J., Tricot, G., Jagannath, S. et al. (1998). Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant, 21, 887–892.
   PubMed Web of Science ®Google Scholar
• Bensinger, W. I., Demirer, T., Buckner, C. D. et al. (1996). Syngeneic marrow transplantation in patients with multiple myeloma. Bone Marrow Transplant, 18, 527–531.
   PubMed Web of Science ®Google Scholar
• Majolino, I., Pearce, R., Taghipour, G. and Goldstone, A. H. (1997). Peripheral blood stem cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry data. J. Clin. Oncol, 15, 509–517.
   PubMed Web of Science ®Google Scholar
• To, L. B., Roberts, M. M., Haylock, D. N. et al. (1992). Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant, 9, 277–284.
   PubMed Web of Science ®Google Scholar
• Jagannath, S., Vesole, D. H., Glenn, L., Crowley, J. and Barlogie, B. (1992). Low risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood, 80, 1666–1672.
   PubMed Web of Science ®Google Scholar
• Bacigalupo, A., Piaggio, G., Podestà, M. et al. (1995). Influence of marrow CFU-GM content on engraftment and survival after allogeneic bone marrow transplantation. Bone Marrow Transplant, 15, 221–226.
   PubMed Web of Science ®Google Scholar
• Mavroudis, D., Read, E., Cottler-Fox, M. et al. (1996). CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic maliganancies, Blood, 88, 3223–3229.
   PubMed Web of Science ®Google Scholar
• Ottinger, H. D., Beelen, D. W., Scheulen, B., Schaefer, U. W. and Grosse-Wilde, H. (1996). Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood, 88, 2775–2779.
   PubMed Web of Science ®Google Scholar
• Glass, B., Uharek, L., Zies, M. et al. (1997). Allogeneic peripheral blood progenitor cell transplantation in a murine model. Evidence for an improved graft-versus-leukemia effect. Blood, 90, 1694–1700.
   PubMed Web of Science ®Google Scholar
• Körbling, M., Przepiorka, D., Huh, Y. O. et al. (1995). Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood, 85, 1655–1658.
   PubMed Web of Science ®Google Scholar
• Bensinger, W. I., Weaver, C. H., Appelbaum, F. R. et al. (1995). Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony stimulating factor. Blood, 85, 1659–1665.
   PubMed Web of Science ®Google Scholar
• Schmitz, N., Dreger, P., Suttorp, M. et al. (1995). Primary transplantation of allogeneic peripheral blood cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood, 85, 1666–1672.
   PubMed Web of Science ®Google Scholar
• Majolino, I., Saglio, G., Scimè, R. et al. (1996). High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Bone Marrow Transplant, 17, 555–560.
   PubMed Web of Science ®Google Scholar
• Bensinger, W. I., Clift, R., Martin, P. et al. (1996). Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood, 88, 2794–2800.
   PubMed Web of Science ®Google Scholar
• Majolino, I., Corradini, P., Scimè, R. et al. (1998). Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant, 22, 449–455.
   PubMed Web of Science ®Google Scholar
• Cavo, M., Bandini, G., Lemoli, R. M. et al. (1998). Allogeneic transplantation with bone marrow or peripheral blood stem cells for multiple myeloma. A multivariate analysis of risk factors on outcome. Bone Marrow Transplant, 21(Suppl 1): S213.
   Google Scholar
• Antin, J. H. (1993). Graft-versus-leukemia: no longer an epiphenomenon. Blood, 82, 2273–2277.
   PubMed Web of Science ®Google Scholar
• Goldman, J. M., Gale, R. P., Horowitz, M. M. et al. (1988). Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Ann. Intern. Med., 108, 806–814.
   PubMed Web of Science ®Google Scholar
• Collins, R. H., Rogers, Z. R., Bennett, M., Kumar, V., Nikein, A. and Fay, J. W. (1992). Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Tranplant, 10, 391–395.
   PubMed Web of Science ®Google Scholar
• Porter, D. L., Roth, M. S., Mc Garigle, C., Ferrara, J. M. L. and Antin, J. H. (1994). Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N. Eng. J. Med., 330, 100–106.
   PubMed Web of Science ®Google Scholar
• Kolb, H. J., Mittermuller, J., Clemm, C. et al. (1990). Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood, 12, 2462–2465.
   Google Scholar
• Kolb, H. J., Schattenberg, A., Goldman, J. M. et al. (1995). Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood, 86, 2041–2050.
   PubMed Web of Science ®Google Scholar
• Glass, B., Majolino, I., Dreger, P. et al. (1997). Allogeneic peripheral blood progenitor cells for the treatment of relapse after bone marrow transplantation. Bone Marrow Transplant, 20, 533–541.
   PubMed Web of Science ®Google Scholar
• Lokhorst, H. M., Schattenberg, A., Cornelissen, J. J., Thomas, L. L. M. and Verdonk, L. F. (1997). Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood, 90, 4206–4211.
   PubMed Web of Science ®Google Scholar
• Tricot, G., Vesole, D. H., Jagannath, S., Hilton, J., Munshi, N. and Barlogie, B. (1996). Graft-versus-myeloma effect: Proof of a principle. Blood, 87, 1196–1198.
   PubMed Web of Science ®Google Scholar
• Collins, R. H. J., Spilberg, O., Drobyski, W. R. et al. (1997). Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol., 15, 433–444.
   PubMed Web of Science ®Google Scholar
• Bertz, H., Burger, J. A., Kunzmann, R., Mertelsmann, R. and Finke, J. (1997). Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect. Leukemia, 11, 281–283.
   PubMed Web of Science ®Google Scholar
• Zomas, A., Stefanoudaki, K., Fisfis, M., Papadaki, T. and Mehta, J. (1998). Graft-versus-myeloma after donor leukocyte infusion: maintenance of marrow remission but extramedullary relapse with plamacytomas. Bone Marrow Transplantation, 21, 1163–1165.
   PubMed Web of Science ®Google Scholar
• Kwak, L. W., Taub, D. D., Duffey, P. L. I. et al. (1995). Transfer of myeloma idiotype-specific immunity from am actively immunized marrow donor. Lancet, 345, 1016–1020.
   PubMed Web of Science ®Google Scholar